STOCK TITAN
  1. Home
  2. News
  3. NTRA

Natera, Inc. - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.

Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.

The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.

Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.

News

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Natera, Inc. (NTRA) reports strong financial results for Q4 2023, showing significant revenue growth and test volume increases. The company achieved total revenues of $311.1 million in Q4 2023, up 43.2% from the previous year, with product revenues growing by 44.3%. Natera processed approximately 2,496,100 tests in 2023, a 20.8% increase from 2022. The company's gross margins improved to 51.4% in Q4 2023. Natera expects 2024 revenue of $1.32 billion-$1.35 billion and continues to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
earnings
-
News

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

Rhea-AI Summary
Natera, Inc. (NTRA) progresses in patent infringement litigation against CareDx with a $96.3 million jury verdict in lost profits and past royalties. The U.S. District Court will decide on future royalties for ongoing AlloSure testing. Discovery and briefing to continue till summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
News

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

Rhea-AI Summary
Natera, Inc. (NTRA) announces that its Signatera MRD test has met coverage requirements from CMS in new indications for ovarian and breast cancer. The test has shown promising results in detecting recurrence early and predicting therapy response, potentially improving outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
News

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

Rhea-AI Summary
Natera, Inc. (NTRA) to release Q4 and year-end 2023 financial results on Feb. 28, 2024. Conference call and webcast to follow. Details provided for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
earnings
-
News

New Study Validates Signatera™ in Endometrial Cancer

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced a study validating its MRD test, Signatera, in endometrial cancer. The study showed that patients who tested Signatera MRD-positive experienced significantly higher rates of recurrence, making Signatera a powerful post-surgical biomarker of recurrence risk for patients with endometrial cancer. The potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer was demonstrated in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Rhea-AI Summary
Natera, Inc. (NTRA) announced a new study demonstrating the effectiveness of its Signatera MRD test in detecting recurrence early in patients with resected stage I-II non-small cell lung cancer. The study showed that clinical management was altered in 100% of patients with a Signatera positive result, highlighting the potential of this test in risk stratification. With NSCLC accounting for 81% of all lung cancer diagnoses in the U.S., this study has significant implications for patient care and cancer management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
News

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties

Rhea-AI Summary
Natera, Inc. (NTRA) has won a patent infringement case against CareDx, Inc., with the jury awarding Natera $83.7 million in lost profits and $12.6 million in past royalties. The jury also found that all asserted claims of Natera's patents are valid and provided an advisory verdict that all asserted claims are valid under 35 U.S.C. Sec. 101. Further proceedings will determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe Natera's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
News

CareDx Issues Statement in Patent Infringement Case

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
News

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™ The first study, AMPLIFY-201, evaluated the ELI-002 cancer vaccine and enrolled 25 patients with solid tumors. Results showed that 21 patients had Signatera-positive status after locoregional treatment, and tumor biomarker responses were observed in 84% of patients. The study highlights the potential utility of ctDNA as a reliable surrogate biomarker for treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
News

Natera Acquires Reproductive Health Assets from Invitae

Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
acquisition

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $171.93 as of January 22, 2025.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 21.0B.

What does Natera, Inc. specialize in?

Natera specializes in preconception and prenatal genetic testing services, including Non-Invasive Prenatal Testing (NIPT) and Horizon Carrier Screening (HCS).

Where is Natera, Inc. headquartered?

Natera, Inc. is headquartered in San Carlos, California.

What is the Panorama Non-Invasive Prenatal Test (NIPT)?

The Panorama NIPT screens for chromosomal abnormalities in a fetus, including twin pregnancies, typically through a blood draw from the mother.

What is the Horizon Carrier Screening (HCS)?

Horizon Carrier Screening (HCS) determines if an individual is a carrier for severe genetic diseases that could be passed to their children.

What is the Signatera Molecular Residual Disease (MRD) Test?

The Signatera MRD Test detects circulating tumor DNA in previously diagnosed cancer patients to assess molecular residual disease and monitor recurrence.

What is the purpose of the Prospera test?

The Prospera test is designed to assess organ transplant rejection.

How has Natera advanced genetic testing?

Natera has leveraged advances from the Human Genome Project and sophisticated proprietary bioinformatic algorithms to deliver highly accurate genetic testing results.

Does Natera offer genetic counseling services?

Yes, Natera provides experienced genetic counseling services to help patients understand their test results and make informed decisions.

What industries does Natera serve?

Natera primarily serves the medical diagnostics and research industries, focusing on prenatal, cancer, and transplant testing.

What makes Natera's tests unique?

Natera's tests are unique due to their high accuracy, leveraging proprietary bioinformatics technology and advances from the Human Genome Project.
Stock NTRA logo
Natera, Inc.

Nasdaq:NTRA

NTRA Rankings

#534 Ranked by Market Cap
N/A Ranked by Dividends

NTRA Stock Data

20.96B
126.19M
3.45%
93.38%
3.06%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
AUSTIN